Infosys Ltd ADR (INFY) was Downgraded by HSBC Securities to ” Hold”. Earlier the firm had a rating of “Buy ” on the company shares. HSBC Securities advised their investors in a research report released on Aug 9, 2016.
Many Wall Street Analysts have commented on Infosys Ltd ADR. Infosys Ltd ADR was Downgraded by Nomura to ” Neutral” on Jul 18, 2016. Infosys Ltd ADR was Downgraded by Credit Suisse to ” Neutral” on Jul 18, 2016. Infosys Ltd ADR was Initiated by Pacific Crest to “Sector Weight” on Jul 12, 2016.
On the company’s financial health, Infosys Ltd ADR reported $15.03 EPS for the quarter, missing the analyst consensus estimate by $ -0.11 based on the information available during the earnings call on Jul 15, 2016. Analyst had a consensus of $15.14. The company had revenue of $167820.00 million for the quarter, compared to analysts expectations of $170687.00 million. The company’s revenue was up 16.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $13.26 EPS.
Infosys Ltd ADR opened for trading at $16.28 and hit $16.34 on the upside on Monday, eventually ending the session at $16.27, with a gain of 0.12% or 0.02 points. The heightened volatility saw the trading volume jump to 68,53,947 shares. Company has a market cap of $37,187 M.
Infosys Limited is engaged in consulting technology outsourcing and next-generation services. The Company’s solutions include application development and maintenance independent validation services infrastructure management engineering services comprising product engineering and life cycle solutions and business process management; Management Consulting enterprise solutions and package implementation systems integration and business intelligence; Products business platforms and solutions and technologies such as cloud computing enterprise mobility digital big data and analytics. Its segments are Financial Services and Insurance Manufacturing Energy and utilities Communication and Services Retail Consumer packaged goods and Logistics Life Sciences and Healthcare and Growth Markets.